Novartis AG (NVS) Stock Research, Analysis & News

Quick Analysis on Novartis AG (NVS) Stock as of January 28, 2020

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Novartis AG (NVS) Stock below)

Novartis AG (NVS) Stock Profile Summary

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division engages in the research, development, manufacture, distribution, and sale of pharmaceuticals in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; and immunology and infectious diseases. The companys Vaccines and Diagnostics division offers preventive vaccines and diagnostic tools. This division provides influenza, meningococcal, pediatric, and traveler vaccines; and blood testing and molecular diagnostics to prevent the spread of infectious diseases. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; anti-infectives; protein or biotechnology-based products; and cytotoxic products, as well as offers biotech manufacturing services to other companies on a contract basis. The companys Consumer Health division consists of three business units: over-the-counter medicines (OTC), Animal Health, and CIBA Vision. OTC offers readily available consumer medicines. Animal Health provides veterinary products for farm and companion animals. CIBA Vision manufactures contact lenses and lens care products. Novartis AG has a strategic alliance with Intercell AG to develop vaccines; a strategic partnership with Lonza, a Swiss pharmaceuticals manufacturing company; and an agreement with Synthetic Genomics Vaccines Inc. to apply synthetic genomics technologies for the development of influenza drugs. The company was founded in 1895 and is headquartered in Basel, Switzerland.

Novartis AG (NVS) Stock Key Statistics Research and Analysis as of January 28, 2020

Novartis AG (NVS) Stock Competitor Research and Analysis

Merck & Co. Inc. (MRK)Pfizer Inc. (PFE)
Sanofi-Aventis (SNY)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)Mylan, Inc. (MYL)
Johnson & Johnson (JNJ)GlaxoSmithKline plc (GSK)

Mutual Funds with Novartis AG (NVS) Stock in its top 10 holdings

FundCategoryNVS Holding Percentage
BBH Core Select NLarge Blend4.25%
DFA International Core Equity IForeign Large Value0.38%
DFA Intl Sustainability Core 1Foreign Large Blend0.45%
DFA TA World ex US Core Equity IForeign Large Blend0.4%
DFA International Vector Equity IForeign Small/Mid Value0.32%
Eaton Vance Global Growth CWorld Stock2.02%
Shelton European Growth & Income DirectEurope Stock5.71%

ETFs with Novartis AG (NVS) Stock in its top 10 holdings

Stock Research on Novartis AG (NVS)

Latest Market News on Novartis AG (NVS)

Click here to find the latest news on Novartis AG (NVS)

Looking for Market Opportunties?

Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Merck & Co. Inc. (MRK)
Pfizer Inc. (PFE)
Sanofi-Aventis (SNY)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)